TAP
MRNA icon

Tounjian Advisory Partners’s Moderna MRNA Stock Holding History

Tounjian Advisory Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.8K Buy
+197
New +$10.2K 0.01% 343

Other funds holding MRNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Tounjian Advisory Partners's MRNA Position: Q2 2026 in Review

Tounjian Advisory Partners opened a new position in Moderna (MRNA) in Q2 2026: 197 shares worth $13.8K. The stake represents 0.01% of the portfolio and ranks #343 among its holdings.

435 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Tounjian Advisory Partners held 197 shares of Moderna worth $13.8K as of Q2 2026.
  • Moderna was a new Tounjian Advisory Partners position in Q2 2026.
  • Moderna made up 0.01% of Tounjian Advisory Partners's portfolio in Q2 2026, its #343 holding.
  • 435 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Tounjian Advisory Partners's 13F filing for Q2 2026, filed 7 Aug 2026.